الفهرس 
Title : Predictive & Prognostic value of Circulating tumor cells in small-cell lung cancer
ContentsOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
Small cell lung cancer (SCLC) has a very aggressive course with high propensity for metastasis. The median overall survival (OS) is about 12–20 months with only 6% to 12% of patients surviving for 5 years after diagnosis even in early stages of the disease. Currently, there are no validated biomarkers to follow the disease activity During treatment of SCLC. Detection of circulating tumor cells (CTCs) is a novel laboratory technique currently in use to determine response to therapy and to predict prognosis in breast, lung, colorectal and prostate cancer. We hypothesize that CTCs may be a valuable biomarker for therapeutic response, and survival in patients with SCLC. The aim of our study is the identification of predictive & prognostic value of Circulating tumor cells in small-cell lung cancer and its effect on the clinical response, PFS and OS.
Design and Methods: this prospective study included 51 patients with small cell lung cancer (SCLC) diagnosed at the National Cancer Institute, Cairo University in the period from 2019 till 2021 with follow up period of 18 months. Detection of Circulating Tumor Cells (CTCs) by flow cytometry: CTCs assessed in 7.5ml of fresh blood at presentation and then after the 2nd cycle Clinical data were obtained from patients’ files.
Results Out of 51 patients of SCLC, all patients with Pretreatment CTCs level ≤5 developed clinical response (17 patients) vs 23(88.5%) of patients with post treatment CTCs level ≤5. Six months PFS for patients with pretreatment CTCs level ≤5 was 94.1% compared to 50 % for patients with pretreatment CTCs level >5 while six months PFS was 92.3% and 36 %for post treatment CTCs respectively. while One year overall survival for patients with pretreatment CTCs level ≤5 was 94.1% compared to 40.8 %for patients with pretreatment CTCs level >5 vs 96.2 % and 18.7 % for post treatment CTCs respectively. This is shows significant Correlation between Pre and post treatment CTCs level with cut-off value of 5 cells with clinical response progression-free survival and overall survival.
Conclusions: There was a significant correlation between CTCs and clinical outcome which will allow us to use CTCs as predictive and prognostic markers in the management of SCLC but more clinical trials are needed to prove our